Industry
Tercica
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
33.3%-53% vs avg
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
Failure Rate
66.7%
2 terminated/withdrawn out of 3 trials
Success Rate
33.3%
-53.2% vs industry average
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
300%
3 of 1 completed trials have results
Key Signals
3 with results
Enrollment Performance
Analytics
Phase 1
2(66.7%)
Phase 2
1(33.3%)
3Total
Phase 1(2)
Phase 2(1)
Activity Timeline
Global Presence
Loading network data...
Clinical Trials (3)
Showing 3 of 3 trials
NCT00684957Phase 1Terminated
Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors
Role: collaborator
NCT00516386Phase 1Completed
Safety Profile of Insulin Like Growth Factor-1 (IGF-I) Administration in Adolescents
Role: collaborator
NCT00764699Phase 2Terminated
Effect of Increlex® on Children With Crohn Disease
Role: collaborator
All 3 trials loaded